Araştırma Makalesi
Yıl 2017,
Cilt: 9 Sayı: 5, 10 - 13, 28.09.2017
Öz
Abstract
Introduction: Cardiovascular diseases
are known as leading causes of death. The ti-rofiban GPIIb / IIIa
receptor antagonist effectively inhibits platelet aggregation.
MeanPlatelet Volume is a marker indicating platelet activation. We aimed
to evaluate the ef-fect of tirofiban on the mean platelet volume in our
study.
Methods:The patients were divided into two groups:
the control group treat with 300mg aspirin 600 mg clopidogrel (n: 20)
and the other group (tirofiban group n: 56) in addition to these two
antiplatelet treatments. Hematological parameters of these two groups
were evaluated before and after treatment.
Results:When the
mean platelet volume was compared before and after the procedure, it
was observed that the mean platelet volume decreased statistically in
the tirofiban group. (8,31 ± 1,12; 7,89 ± 0,81 p <0,001).
Conclusion:in
our study has been shown that the use of tirofiban in patients
withintense thrombus load a positive effect on the reduction of mean
platelet volume.
Kaynakça
- Kaynaklar 1. Windecker S, Kolh P, Alfonso F, Collet JP, Cremer J, Falk Vet al : ESC/EACTS Guidelines on myocardial revasculariza-tion: The task force on myocardial revascularization of the Eu-ropean Society of Cardiology (ESC) and the European Asso-ciation for Cardio-Thoracic Surgery (EACTS) developed withthe special contribution of the European Association of per-cutaneous cardiovascular interventions (EAPCI). Eur HeartJ 2014; 35, 2541–2619 [PubMed] 2. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, Alfonso F, Ma-caya C, Bass TAet al : Variability in individual responsive-ness to clopidogrel: Clinical implications, management, andfuture perspectives. J Am Coll Cardiol 2007; 49, 1505–1516[PubMed] 3. Aradi D, Tornyos A, Pinter T, Vorobcsuk A, Konyi A, Falu-kozy Jet al : Optimizing P2Y12 receptor inhibition in patientswith acute coronary syndrome on the basis of platelet func-tion testing: Impact of prasugrel and high-dose clopidogrel.J Am Coll Cardiol 2014; 63, 1061–1070 [PubMed] 4. Valgimigli M, Biondi-Zoccai G, Tebaldi M, van ’t Hof AW,Campo G, Hamm C, ten Berg J, Bolognese L, Saia F, DanziGB, Briguori C, et al : Tirofiban as adjunctive therapy for acu-te coronary syndromes and percutaneous coronary interven-tion: A meta-analysis of randomized trials. Eur Heart J 31,35–49 (2010) [PubMed] 5.Park Y, Schoene N, Harris W. Mean platelet volume as an in-dicator of platelet activation: methodological issues. Plate-lets 2002;13(5–6): 301–6 6. Boos CJ, Balakrishnan B, Lip GY. The effects of coronary ar-tery disease severity on time-dependent changes in platelet ac-tivation indices in stored whole blood. J Thromb Thromboly-sis 2008;25(2):135–40 7. Martin JF, Bath PM, Burr ML. Inuence of platelet size on out-come after myocardial infarction. Lancet 1991;338(8780):1409–11. 8. Chu SG, Becker RC, Berger PB, Bhatt DL, Eikelboom JW, Kon-kle B, et al. Mean platelet volume as a predictor of cardiovas-cular risk: a systematic review and meta-analysis. J ThrombHaemost 2010;8(1):148–56 9. Bath P, Algert C, Chapman N, Neal B. Association of meanplatelet volume with risk of stroke among 3134 individuals withhistory of cerebrovascular disease. Stroke 2004;35(3):622–6 10.Ten Berg, J. M., van’t Hof, A. W., Dill, T., et al. (2010). Ef-fect of early, pre-hospital initiation of high bolus dose tirofi-ban in patients with ST-segment elevation myocardial infarc-tion on short- and long-term clinical outcome. Journal of theAmerican College of Cardiology, 55, 2446–2455 11. Kupo P , Aradı D , Tornyos A, Füzesı MT, Komocsı A. Assess-ment of platelet function in patients receiving tirofiban earlyafter primary coronary intervention. Interventional Medici-ne & Applied Science, Vol. 2016; 8 : 135–140 12. Karpatkin S. Heterogeneity of human platelets. II. Functio-nal evidence suggestive of young and old platelets. J Clin In-vest 1969;48(6):1083-7. 13. Martin JF, Trowbridge EA, Salmon GL, Plumb J. The biolo-gical significance of platelet volume: its relationship tobleeding time, platelet thromboxane B2 production and me-gakaryocyte nuclear DNA concentration. Thromb Res1983;32(5):443- 60. 14. Van der Loo B, Martin JF. A role for changes in platelet pro-duction in the cause of acute coronary syndromes. Arteriosc-ler Thromb Vasc Biol 1999;19(3):672-9 15.Park Y, Schoene N, Harris W. Mean platelet volume as an in-dicator of platelet activation: methodological issues. Plate-lets 2002;13(5–6): 301–6. 16. Boos CJ, Balakrishnan B, Lip GY. The effects of coronary ar-tery disease severity on time-dependent changes in platelet ac-tivation indices in stored whole blood. J Thromb Thromboly-sis 2008;25(2):135–40. 17. Martin JF, Bath PM, Burr ML. Influence of platelet size onoutcome after myocardial infarction. Lancet 1991;338(8780):1409–11. 18. Chu SG, Becker RC, Berger PB, Bhatt DL, Eikelboom JW, Kon-kle B, et al. Mean platelet volume as a predictor of cardiovas-cular risk: a systematic review and meta-analysis. J ThrombHaemost 2010;8(1):148–56. 19. Bath P, Algert C, Chapman N, Neal B. Association of meanplatelet volume with risk of stroke among 3134 individuals withhistory of cerebrovascular disease. Stroke 2004;35622–6. 20. Icli A, Aksoy F, Turker Y, Uysal B A, Alpay M F, Dogan Aetal : Relationship Between Mean Platelet Volume and Pulmo-nary Embolism in Patients With Deep Vein Thrombosis. He-art, Lung and Circulation 2015 xx, 1–6 21. Behan MW, Storey RF. Antiplatelet therapy in cardiovascu-lar disease. Postgrad Med J 2004;80:155-164
Yıl 2017,
Cilt: 9 Sayı: 5, 10 - 13, 28.09.2017
Öz
Öz
Giriş: Kardiyovasküler hastalıklar önde gelen ölüm nedenleri olarak bilinmektedir.Tirofiban GPIIb / IIIa reseptör antagonisti olup , trombosit agregasyonunu etkili bir şekilde inhibe eder. Ortalama Trombosit Hacmi trombosit aktivasyonunu gösteren bir markerdir. Çalışmamızda tirofibanın ortalam trombosit hacmine etkisini değerlendirmeği amaçladık.
Yöntem: Çalışmaya tedavisine 300 mg aspirin 600 mg klopidogrel verilen grup (n:20)ve bu ikili antiplatelet tedaviye ek olarak tirofiban eklenen grup (n:56) olmak üzereiki gruba ayrıldı. Bu iki gurubun tedavi öncesi ve sonrası hematolojik parametreleri değerlendirildi. Bulgular: İşlem öncesi ve sonrası ortalam trombosit hacmi karşılaştırıldığında ortalama trombosit hacminin tirofiban verilen gurupta istatistiksel olarak anlamlı şekilde düştüğü izlendi. (8,31±1,12; 7,89±0,81 p<0,001).
Sonuç:Çalışmamızda yoğun trombüs yükü olan hastalarda tirofibanın kullanılmasının ortalama trombosit hacmi nin azalaması üzerine olumlu etkisi olduğu gösterilmiştir.
Anahtar Kelimeler
Kaynakça
- Kaynaklar 1. Windecker S, Kolh P, Alfonso F, Collet JP, Cremer J, Falk Vet al : ESC/EACTS Guidelines on myocardial revasculariza-tion: The task force on myocardial revascularization of the Eu-ropean Society of Cardiology (ESC) and the European Asso-ciation for Cardio-Thoracic Surgery (EACTS) developed withthe special contribution of the European Association of per-cutaneous cardiovascular interventions (EAPCI). Eur HeartJ 2014; 35, 2541–2619 [PubMed] 2. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, Alfonso F, Ma-caya C, Bass TAet al : Variability in individual responsive-ness to clopidogrel: Clinical implications, management, andfuture perspectives. J Am Coll Cardiol 2007; 49, 1505–1516[PubMed] 3. Aradi D, Tornyos A, Pinter T, Vorobcsuk A, Konyi A, Falu-kozy Jet al : Optimizing P2Y12 receptor inhibition in patientswith acute coronary syndrome on the basis of platelet func-tion testing: Impact of prasugrel and high-dose clopidogrel.J Am Coll Cardiol 2014; 63, 1061–1070 [PubMed] 4. Valgimigli M, Biondi-Zoccai G, Tebaldi M, van ’t Hof AW,Campo G, Hamm C, ten Berg J, Bolognese L, Saia F, DanziGB, Briguori C, et al : Tirofiban as adjunctive therapy for acu-te coronary syndromes and percutaneous coronary interven-tion: A meta-analysis of randomized trials. Eur Heart J 31,35–49 (2010) [PubMed] 5.Park Y, Schoene N, Harris W. Mean platelet volume as an in-dicator of platelet activation: methodological issues. Plate-lets 2002;13(5–6): 301–6 6. Boos CJ, Balakrishnan B, Lip GY. The effects of coronary ar-tery disease severity on time-dependent changes in platelet ac-tivation indices in stored whole blood. J Thromb Thromboly-sis 2008;25(2):135–40 7. Martin JF, Bath PM, Burr ML. Inuence of platelet size on out-come after myocardial infarction. Lancet 1991;338(8780):1409–11. 8. Chu SG, Becker RC, Berger PB, Bhatt DL, Eikelboom JW, Kon-kle B, et al. Mean platelet volume as a predictor of cardiovas-cular risk: a systematic review and meta-analysis. J ThrombHaemost 2010;8(1):148–56 9. Bath P, Algert C, Chapman N, Neal B. Association of meanplatelet volume with risk of stroke among 3134 individuals withhistory of cerebrovascular disease. Stroke 2004;35(3):622–6 10.Ten Berg, J. M., van’t Hof, A. W., Dill, T., et al. (2010). Ef-fect of early, pre-hospital initiation of high bolus dose tirofi-ban in patients with ST-segment elevation myocardial infarc-tion on short- and long-term clinical outcome. Journal of theAmerican College of Cardiology, 55, 2446–2455 11. Kupo P , Aradı D , Tornyos A, Füzesı MT, Komocsı A. Assess-ment of platelet function in patients receiving tirofiban earlyafter primary coronary intervention. Interventional Medici-ne & Applied Science, Vol. 2016; 8 : 135–140 12. Karpatkin S. Heterogeneity of human platelets. II. Functio-nal evidence suggestive of young and old platelets. J Clin In-vest 1969;48(6):1083-7. 13. Martin JF, Trowbridge EA, Salmon GL, Plumb J. The biolo-gical significance of platelet volume: its relationship tobleeding time, platelet thromboxane B2 production and me-gakaryocyte nuclear DNA concentration. Thromb Res1983;32(5):443- 60. 14. Van der Loo B, Martin JF. A role for changes in platelet pro-duction in the cause of acute coronary syndromes. Arteriosc-ler Thromb Vasc Biol 1999;19(3):672-9 15.Park Y, Schoene N, Harris W. Mean platelet volume as an in-dicator of platelet activation: methodological issues. Plate-lets 2002;13(5–6): 301–6. 16. Boos CJ, Balakrishnan B, Lip GY. The effects of coronary ar-tery disease severity on time-dependent changes in platelet ac-tivation indices in stored whole blood. J Thromb Thromboly-sis 2008;25(2):135–40. 17. Martin JF, Bath PM, Burr ML. Influence of platelet size onoutcome after myocardial infarction. Lancet 1991;338(8780):1409–11. 18. Chu SG, Becker RC, Berger PB, Bhatt DL, Eikelboom JW, Kon-kle B, et al. Mean platelet volume as a predictor of cardiovas-cular risk: a systematic review and meta-analysis. J ThrombHaemost 2010;8(1):148–56. 19. Bath P, Algert C, Chapman N, Neal B. Association of meanplatelet volume with risk of stroke among 3134 individuals withhistory of cerebrovascular disease. Stroke 2004;35622–6. 20. Icli A, Aksoy F, Turker Y, Uysal B A, Alpay M F, Dogan Aetal : Relationship Between Mean Platelet Volume and Pulmo-nary Embolism in Patients With Deep Vein Thrombosis. He-art, Lung and Circulation 2015 xx, 1–6 21. Behan MW, Storey RF. Antiplatelet therapy in cardiovascu-lar disease. Postgrad Med J 2004;80:155-164
Toplam 1 adet kaynakça vardır.
Ayrıntılar
| Birincil Dil | Türkçe |
|---|---|
| Bölüm | makaleler |
| Yazarlar | |
| Yayımlanma Tarihi | 28 Eylül 2017 |
| Yayımlandığı Sayı | Yıl 2017 Cilt: 9 Sayı: 5 |
